Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916446 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Viaskin Peanut to Treat Peanut Allergy
A Phase 3 study of Peanut Allergy, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
- 20
- Study locations
NCT02916446 is a Phase 3 study of Peanut Allergy that has completed, run by DBV Technologies. The registered enrollment target is 393 participants, above the 184-participant average among 13 other Peanut Allergy trials with a reported enrollment target (114% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02916446, a Phase 3 study of Peanut Allergy, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Viaskin Peanut 250 mcg
Study Locations (20)
California
- Allergy & Asthma Associates of Southern California - Mission Viejo
- Palos Verdes Medical Group - Rolling Hills Estates
- Stanford University School of Medicine - Stanford
Colorado
- Children's Hospital Colorado - Aurora
- National Jewish Health - Denver
Illinois
- Ann & Robert H. Lurie Children's Hospital of CHicago - Chicago
- Sneeze, Wheeze and Itch Associates,Clinical Research - Normal
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Childrens' Hospital - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
Arkansas
- Arkansas Children's Hospital - Little Rock
Florida
- Sarasota Clinical Research - Sarasota
Georgia
- Atlanta Allergy & Asthma Clinic - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02916446
The ClinicalTrials.gov registry entry for NCT02916446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 13 other Peanut Allergy trials with a reported enrollment target (114% higher). The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02916446 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT02916446 about?
NCT02916446 is a clinical study titled "Safety Study of Viaskin Peanut to Treat Peanut Allergy". This study evaluates the safety of Viaskin Peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. Subjects will receive either Viaskin Peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a perio...
What is the current status of trial NCT02916446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2016-10. Estimated completion is 2020-10-07.
What conditions does trial NCT02916446 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT02916446?
The interventions under investigation include: Placebo (BIOLOGICAL), Viaskin Peanut 250 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02916446?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02916446 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
COMPLETED · Phase 3
-
AR101 Real-World Open-Label Extension Study
COMPLETED · Phase 3
-
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
COMPLETED · Phase 3
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.